NES-ZIONA, Israel, May 31, 2013 /PRNewswire/ -- PROLOR Biotech,
Inc. (NYSE MKT: PBTH), a clinical stage company developing next
generation biobetter therapeutic proteins, today announced that
company management will give a corporate presentation at the
Jefferies 2013 Global Healthcare Conference, being held at the
Grand Hyatt Hotel in New York
City. The presentation is scheduled for June 4, 2013 at 4:30 pm
ET.
A live webcast of the company's presentation will be available
at the Investors section of PROLOR's website at
www.prolor-biotech.com/?CategoryID=215, or at
http://wsw.com/webcast/jeff77/pbth/. An audio replay of the
presentation will be available on the PROLOR website approximately
one hour after the presentation and will be archived for at least
30 days.
The Jefferies 2013 Global Healthcare Conference will be held
June 3-6, 2013. For more information,
visit http://www.jefferies.com/OurFirm/Conferences/325/70.
ABOUT PROLOR
PROLOR Biotech, Inc. is a clinical stage
biopharmaceutical company applying unique technologies, including
patented CTP technology and its long-acting reversible-pegylation
technology, primarily to develop longer-acting proprietary versions
of already approved therapeutic proteins that currently generate
billions of dollars in annual global sales. The CTP technology is
applicable to virtually all proteins. PROLOR is developing a
long-acting version of human growth hormone, which is currently
being assessed in a Phase III pivotal trial. It also is developing
long-acting versions of Factor VIIa and Factor IX for hemophilia
and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and
obesity, all of which are in preclinical development. For more
information, visit www.prolor-biotech.com.
PROLOR
CONTACT:
|
MEDIA
CONTACT:
|
Shai Novik,
President
|
Barbara
Lindheim
|
PROLOR Biotech,
Inc.
|
BLL
Partners
|
Tel: +1 866
644-7811
|
+1 212
584-2276
|
Email:
shai@prolor-biotech.com.
|
blindheim@bllbiopartners.com
|
SOURCE PROLOR Biotech, Inc.